Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
6.55
-0.04 (-0.61%)
Aug 26, 2026, 12:12 PM EDT - Market open
Prelude Therapeutics Market Cap
Prelude Therapeutics has a market cap or net worth of $674.62 million as of August 26, 2026. Its market cap has increased by 597.72% in one year.
Market Cap
674.62M
Enterprise Value
540.51M
1-Year Change
597.72%
Ranking
Category
Stock Price
$6.55
ChartMarket Cap Chart
Since the IPO on September 25, 2020, Prelude Therapeutics's market cap has decreased from $806.64M to $674.62M, a decrease of -16.37%. That is a compound annual growth rate of -2.97%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 26, 2026 | 674.62M | 182.32% |
| Dec 31, 2025 | 238.95M | 147.03% |
| Dec 31, 2024 | 96.73M | -70.04% |
| Dec 29, 2023 | 322.85M | 12.32% |
| Dec 30, 2022 | 287.43M | -50.22% |
| Dec 31, 2021 | 577.35M | -80.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 25, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Zevra Therapeutics | 703.10M |
| Phathom Pharmaceuticals | 688.66M |
| AgomAb Therapeutics NV | 688.11M |
| OmniAb | 686.24M |
| Eikon Therapeutics | 673.27M |
| CorMedix | 665.64M |
| MapLight Therapeutics | 654.13M |
| Contineum Therapeutics | 643.32M |